Primary care COPD patients compared with large pharmaceutically-sponsored COPD studies: An UNLOCK validation study

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Kruis, Annemarije L ^a   Ställberg, Björn ^b   Jones, Rupert C M ^c   Tsiligianni, Ioanna G ^d,e   Lisspers, Karin ^b   Van Der Molen, Thys ^d   Kocks, Jan Willem H ^d   Chavannes, Niels H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF PLYMOUTH   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e Agia Barbara Health Care Centre   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DATA BASE; DISEASE EXACERBATION; DISEASE SEVERITY; EXTERNAL VALIDITY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENDER; GREECE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRIMARY MEDICAL CARE; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SWEDEN; UNITED KINGDOM; VALIDATION STUDY; AGE DISTRIBUTION; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; MIDDLE AGED; PRACTICE GUIDELINE; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEX RATIO;

AGE DISTRIBUTION; AGED; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SEX DISTRIBUTION;

EID: 84897131975     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090145     Document Type: Article

References (43)

1. Pierson DJ (2006) Clinical practice guidelines for chronic obstructive pulmonary disease: a review and comparison of current resources. Respiratory Care 51: 277-288.
2. Glaab T, Banik N, Rutschmann OT, Wencker M (2006) National survey of guideline-compliant COPD management among pneumologists and primary care physicians. COPD 3: 141-148. (Pubitemid 44196024)
3. Aisanov Z, Bai C, Bauerle O, Colodenco FD, Feldman C et al. (2012) Primary care physician perceptions on the diagnosis and management of chronic obstructive pulmonary disease in diverse regions of the world. Int J Chron Obstruct Pulmon Dis 7: 271-282. 10.2147/COPD.S28059 [doi];copd-7-271 [pii].
4. Salinas GD, Williamson JC, Kalhan R, Thomashow B, Scheckermann JL et al. (2011) Barriers to adherence to chronic obstructive pulmonary disease guidelines by primary care physicians. Int J Chron Obstruct Pulmon Dis 6: 171-179. 10.2147/COPD.S16396 [doi].
5. Herland K, Akselsen JP, Skjonsberg OH, Bjermer L (2005) How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? Respir Med 99: 11-19. (Pubitemid 40017378)
6. Travers J, Marsh S, Caldwell B, Williams M, Aldington S et al. (2007) External validity of randomized controlled trials in COPD. Respir Med 101: 1313-1320. S0954-6111(06)00508-7 [pii];10.1016/j.rmed.2006.10.011 [doi].
7. Rothwell PM (2006) Factors that can affect the external validity of randomised controlled trials. PLoS Clin Trials 1: e9. 10.1371/journal.pctr. 0010009 [doi].
8. Global Initiative for Chronic Obstructive Lung Disease (2013) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available from: http://www.goldcopd.org/. Accessed 2012 Dec 31.
9. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA et al. (2000) Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320: 1297-1303. (Pubitemid 30245717)
10. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N et al. (2003) Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361: 449-456. S0140-6736(03)12459-2 [pii];10.1016/S0140-6736(03)12459-2 [doi].
11. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C et al. (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356: 775-789. 356/8/775 [pii];10.1056/ NEJMoa063070 [doi].
12. Decramer M, Celli B, Kesten S, Lystig T, Mehra S et al. (2009) Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 374: 1171-1178. S0140-6736(09)61298-8 [pii];10.1016/S0140-6736(09) 61298-8 [doi].
13. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H et al. (2010) Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 363: 1128-1138. 10.1056/NEJMoa0909883 [doi].
14. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Molken MP et al. (2011) Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 364: 1093-1103. 10.1056/NEJMoa1008378 [doi].
15. Chavannes N, Stallberg B, Lisspers K, Roman M, Moran A et al. (2010) UNLOCK: Uncovering and Noting Long-term Outcomes in COPD to enhance knowledge. Prim Care Respir J 19: 408. RHI-046-10 [pii];10.4104/pcrj.2010.00084 [doi].
16. Jones RC, Dickson-Spillmann M, Mather MJ, Marks D, Shackell BS (2008) Accuracy of diagnostic registers and management of chronic obstructive pulmonary disease: the Devon primary care audit. Respir Res 9: 62. 1465-9921-9-62 [pii];10.1186/1465-9921-9-62 [doi].
17. Chavannes NH, Grijsen M, van den Akker M, Schepers H, Nijdam M et al. (2009) Integrated disease management improves one-year quality of life in primary care COPD patients: a controlled clinical trial. Prim Care Respir J 18: 171-176. pcrj-2008-06-0067 [pii];10.3132/pcrj.2009.00003 [doi].
18. Kruis AL, Boland MR, Schoonvelde CH, Assendelft WJ, Molken MP et al. (2013) RECODE: Design and baseline results of a cluster randomized trial on cost-effectiveness of integrated COPD management in primary care. BMC Pulm Med 13: 17. 1471-2466-13-17 [pii];10.1186/1471-2466-13-17 [doi].
19. Kocks J, de Jong C, Berger MY, Kerstjens HA, van der Molen T (2013) Putting health status guided COPD management to the test: protocol of the MARCH study. BMC Pulm Med 13: 41. 1471-2466-13-41 [pii];10.1186/1471-2466-13-41 [doi].
20. Tsiligianni IG, van der Molen T, Moraitaki D, Lopez I, Kocks JW et al. (2012) Assessing health status in COPD. A head-to-head comparison between the COPD assessment test (CAT) and the clinical COPD questionnaire (CCQ). BMC Pulm Med 12: 20. 1471-2466-12-20 [pii];10.1186/1471-2466-12-20 [doi].
21. Sundh J, Janson C, Lisspers K, Montgomery S, Stallberg B (2012) Clinical COPD Questionnaire score (CCQ) and mortality. Int J Chron Obstruct Pulmon Dis 7: 833-842. 10.2147/COPD.S38119 [doi];copd-7-833 [pii].
22. Sundh J, Janson C, Lisspers K, Stallberg B, Montgomery S (2012) The Dyspnoea, Obstruction, Smoking, Exacerbation (DOSE) index is predictive of mortality in COPD. Prim Care Respir J 21: 295-301. pcrj-2012-04-0066 [pii];10.4104/pcrj.2012.00054 [doi].
23. Dutch CCMO guidelines.(2013) Available from: http://www.ccmo-online.nl/ main.asp?pid = 1&taal = 1.Accessed Jan 31 2014.
24. Spencer S, Calverley PM, Burge PS, Jones PW (2004) Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 23: 698-702. (Pubitemid 38618138)
25. Jones PW, Willits LR, Burge PS, Calverley PM (2003) Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 21: 68-73. (Pubitemid 36150303)
26. Celli B, Vestbo J, Jenkins CR, Jones PW, Ferguson GT et al.(2011) Sex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experience. Am J Respir Crit Care Med 183: 317-322. 201004-0665OC [pii];10.1164/rccm.201004-0665OC [doi].
27. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR et al. (2008) Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 178: 332-338. 200712-1869OC [pii];10.1164/rccm.200712-1869OC [doi].
28. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA et al. (2009) Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 10: 59. 1465-9921-10-59 [pii];10.1186/1465-9921-10-59 [doi].
29. Vestbo J, TORCH study group (2004). The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J 24: 206-210.
30. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S et al. (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359: 1543-1554. NEJMoa0805800 [pii];10.1056/NEJMoa0805800 [doi].
31. Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD et al. (2010) Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 11: 122. 1465-9921-11-122 [pii];10.1186/1465-9921-11-122 [doi].
32. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F et al. (2008) Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J 31: 869-873. 09031936.00111707 [pii];10.1183/09031936. 00111707 [doi].
33. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PWet al. (1999) Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 54: 581-586. (Pubitemid 29296676)
34. Jones PW, Quirk FH, Baveystock CM (1991) The St George's Respiratory Questionnaire. Respir Med 85 Suppl B: 25-31.
35. van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS et al. (2003) Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes 1: 13.
36. Menezes AM, Perez-Padilla R, Jardim JR, Muino A, Lopez MV et al. (2005) Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 366: 1875-1881. S0140-6736(05)67632-5 [pii];10.1016/S0140-6736(05)67632-5 [doi].
37. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P et al. (2007) International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 370: 741-750. S0140-6736(07)61377-4 [pii];10.1016/S0140-6736(07)61377-4 [doi].
38. Rabe KF, Wedzicha JA (2011) Controversies in treatment of chronic obstructive pulmonary disease. Lancet 378: 1038-1047. S0140-6736(11)61295-6 [pii];10.1016/S0140-6736(11)61295-6 [doi].
39. Miravitlles M, de la Roza C, Naberan K, Lamban M, Gobartt E et al. (2007) Use of spirometry and patterns of prescribing in COPD in primary care. Respir Med 101: 1753-1760. S0954-6111(07)00096-0 [pii];10.1016/j.rmed.2007.02. 019 [doi].
40. Bourbeau J, Sebaldt RJ, Day A, Bouchard J, Kaplan A et al. (2008) Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study. Can Respir J 15: 13-19. (Pubitemid 351575058)
41. White P, Thornton H, Pinnock H, Georgopoulou S, Booth HP (2013) Overtreatment of COPD with inhaled corticosteroids-implications for safety and costs: cross-sectional observational study. PLoS One 8: e75221. 10.1371/journal.pone.0075221 [doi];PONE-D-13-09654 [pii].
42. de Miguel-Diez J, Carrasco-Garrido P, Rejas-Gutierrez J, Martin-Centeno A, Gobartt-Vazquez E et al. (2011) Inappropriate overuse of inhaled corticosteroids for COPD patients: impact on health costs and health status. Lung 189: 199-206. 10.1007/s00408-011-9289-0 [doi].
43. Kim AM, Tingen CM, Woodruff TK (2010) Sex bias in trials and treatment must end. Nature 465: 688-689. 465688a [pii];10.1038/465688a [doi].